Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

Inclusion Criteria:

• Patients >18 years old.

• Echocardiogram with ejection fraction > 50%

• Patients must present at least one of the following items to be included in thestudy: Patients with a previous diagnosis of Heart Failure with Reduced EjectionFraction (HFrEF) who have improved on the echocardiogram to an ejection fractionabove 50%, patients with a previous ejection fraction between 40-49% who haveprogressed to ejection fraction above 50%. For these groups there is no need toperform the score for heart failure with preserved ejetion fraction score (since thediagnosis of HF was already known). Patients with signs/symptoms of HFpEF, whopresent structural morphological changes such as left atrium enlargement or leftventricular hypertrophy (LVH).

• After recently undergoing the score for heart failure with preserved ejetionfraction score (H2FPEF), patients who present scores that place them at least at anintermediate probability of HFpEF would be eligible for entry into the study.

• Signing the consent form

Exclusion Criteria:

• Patient with type I DM

• Estimated glomerular filtration rate (eGFR), using the Chronic Kidney DiseaseEpidemiology (CKD EPI) equation, with a cutoff of <20 mL/mm/1.73m2

• Patient currently using SGLT2 antagonists

• Patient with a history of allergic reaction or significant sensitivity toempagliflozin

• Female patient who is pregnant or considering becoming pregnant during the study orfor 3 months after the last dose of study medication

• Patients that are breastfeeding

• Patients considered by the investigator, for any reason, to be an unsuitablecandidate for the study

• Patients with a previous diagnosis of HFpEF who presents a low probability ofdiagnosis after being re-stratified by the previously mentioned score

• Patients unable to walk or understand/comply with the study protocol.